Apenas manchetes de alto sinal - eventos macro, resultados, M&A, regulatório. Listicles e clickbait de analistas filtrados por padrão. Atualizado a cada hora.
Roivant Sciences (NASDAQ:ROIV) said it expects a busy second half of 2026, with a potential launch of brepocitinib in dermatomyositis, several clinical readouts and additional regulatory discussions across its pipeline. Chief Executive Officer Matt Gline characterized the quarter as relatively quie
The company says it expects to have mFlusiva ready for the upcoming 2026-2027 flu season, which runs from roughly October to May.
Moderna (MRNA) is back in focus after the US Food and Drug Administration approved mFLUSIVA, the company’s mRNA based flu vaccine for adults aged 50 and over, sparking renewed interest in the stock. See our latest analysis for Moderna. The FDA approval of mFLUSIVA comes after a period of sharp swings in Moderna’s share price, with a 1-month share price return down 31.23% but a year to date share price return up 82.29%. At the same time, the 1-year total shareholder return of 110.61% contrasts...
Roivant said its first quarter was relatively quiet operationally but positioned the company for a more active second half of 2026, with a potential launch of brepocitinib in dermatomyositis, multiple clinical readouts and further updates from Immunovant (NASDAQ:IMVT). Chief Executive Officer Matt
Roivant Sciences Ltd (ROIV) reports robust financials and key clinical milestones, including the brepocitinib launch and Moderna settlement, while navigating pipeline uncertainties.
Moderna has secured FDA approval for its flu vaccine mFLUSIVA. But does that warrant buying MRNA shares today? Let’s find out!
The approval makes mFLUSIVA Moderna’s fourth FDA-cleared product and the first messenger RNA-based flu vaccine.
Moderna stock wavered Thursday after the Food and Drug Administration approved its mRNA-based flu shot, now called mFlusiva.
Shares in Moderna ticked higher after the biotech secured Food and Drug Administration approval for its mRNA flu vaccine for use in adults aged 50 and older. The FDA's decision capped an arduous seven-month process that included a rare refusal by the regulator to consider the shot.
Moderna’s mRNA-based flu vaccine, mFlusiva, is approved by the Food and Drug Administration for adults aged 50 and over.
News of the day for Aug. 6, 2026
Moderna (NASDAQ:MRNA) announced on Thursday that the U. S.
The Food and Drug Administration approved Moderna’s mRNA-based flu vaccine for adults ages 50 and older, clearing the first shot of its kind after a review process that nearly collapsed in February. The vaccine, called mFlusiva, uses the same mRNA technology as Moderna’s Covid-19 shots. It could reach pharmacies in time for the coming flu season, which typically starts in the fall.
Moderna Inc. (NASDAQ:MRNA) stock rose in Wednesday premarket trading after gaining 3.4% in the previous session, as investors reacted to the company’s latest progress in expanding its infectious disease pipeline with an investigational Ebola vaccine. Moderna Begins Phase 1 Trial For Ebola Vaccine Moderna has initiated a Phase 1 clinical trial evaluating mRNA-1469, an investigational vaccine designed to prevent Bundibugyo ebolavirus disease, for which no licensed vaccines currently exist. The stu
Despite Moderna's stellar outperformance over the past year, Wall Street analysts remain cautious about the stock's longer-term prospects.
President Donald Trump discussed efforts to de-escalate US-Iran tensions with Qatari Emir Tamim bin Hamad Al Thani.
These innovative biotech companies should reap the benefits of their breakthroughs.
Moderna began a Phase 1 clinical trial of its experimental vaccine mRNA-1469 targeting the Bundibugyo strain of Ebola virus.
Moderna’s vaccine candidate targets a species of ebolavirus behind a deadly outbreak in the Democratic Republic of the Congo.
The drugmaker posts a narrower-than-expected quarterly loss fueled by growth in its oncology segment.
Decisions are due by August 23 at the latest on therapies ranging from an mRNA flu vaccine to a gene therapy for a rare metabolic disorder, putting biotech investors on high alert.
Moderna (MRNA) is facing several vaccine headwinds in the near to medium term, particularly for its
Moderna reported its Q2 update alongside news that its lead norovirus vaccine candidate did not meet early success criteria in a Phase 3 interim analysis, so the trial will continue for further evaluation. The company is awaiting an FDA decision on its seasonal influenza vaccine, mFLUSIVA, which is expected by early August. Management paired these pipeline updates with Q2 results that were ahead of expectations and a revised outlook for operating expenses. For investors watching...
Moby summary of Moderna, Inc.'s Q2 2026 earnings call
Moderna Inc (MRNA) exceeds Q2 revenue guidance and advances key vaccines, but faces delays in norovirus trial and oncology readouts.
Moderna's Q2 revenue tops estimates, but shares fall after its phase III norovirus vaccine study misses early success criteria.
The company topped Wall Street loss estimates, but its norovirus vaccine missed a key trial goal, sending shares lower
Moderna (NASDAQ:MRNA) reported second-quarter revenue of $145 million, exceeding the high end of its prior guidance range, while continuing to reduce costs and advance programs spanning respiratory vaccines, oncology and rare diseases. The company posted a net loss of $782 million, or $1.97 per sha
Moderna (MRNA) delivered earnings and revenue surprises of 0.00% and +14.49%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
We use Google Analytics to count anonymous page views and understand which content gets read. No ads, no profiles. Decline keeps you on cookieless mode. Details.
